Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Preferred Stock Liabilities (2019 - 2020)

Avidity Biosciences (RNA) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $136.9 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Preferred Stock Liabilities changed N/A year-over-year to $136.9 million, compared with a TTM value of $136.9 million through Mar 2020, changed N/A, and an annual FY2019 reading of $134.7 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $136.9 million for Q1 2020 at Avidity Biosciences, up from $134.7 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $136.9 million in Q1 2020 and bottomed at $32.6 million in Q2 2019.